ImmunityBio (IBRX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$256.9 million.
- ImmunityBio's Enterprise Value fell 9856.39% to -$256.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$256.9 million, marking a year-over-year decrease of 9856.39%. This contributed to the annual value of -$148.8 million for FY2024, which is 4392.11% up from last year.
- According to the latest figures from Q3 2025, ImmunityBio's Enterprise Value is -$256.9 million, which was down 9856.39% from -$152.7 million recorded in Q2 2025.
- ImmunityBio's Enterprise Value's 5-year high stood at -$49.0 million during Q2 2023, with a 5-year trough of -$318.9 million in Q4 2021.
- Moreover, its 5-year median value for Enterprise Value was -$129.4 million (2024), whereas its average is -$148.6 million.
- Per our database at Business Quant, ImmunityBio's Enterprise Value skyrocketed by 6560.3% in 2022 and then crashed by 34260.62% in 2024.
- Over the past 5 years, ImmunityBio's Enterprise Value (Quarter) stood at -$318.9 million in 2021, then surged by 65.6% to -$109.7 million in 2022, then tumbled by 141.99% to -$265.4 million in 2023, then skyrocketed by 43.92% to -$148.8 million in 2024, then tumbled by 72.6% to -$256.9 million in 2025.
- Its Enterprise Value stands at -$256.9 million for Q3 2025, versus -$152.7 million for Q2 2025 and -$60.6 million for Q1 2025.